Curis (NASDAQ:CRIS) Announces Earnings Results

by · The Markets Daily

Curis (NASDAQ:CRIS – Get Free Report) posted its earnings results on Friday. The biotechnology company reported ($4.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.95) by $2.93, FiscalAI reports.

Curis Trading Down 3.7%

Shares of NASDAQ:CRIS traded down $0.07 during mid-day trading on Friday, reaching $1.80. The company had a trading volume of 470,403 shares, compared to its average volume of 266,000. Curis has a one year low of $1.54 and a one year high of $39.00. The company’s 50-day moving average price is $5.84 and its 200-day moving average price is $11.74. The firm has a market cap of $3.76 million, a price-to-earnings ratio of -0.08 and a beta of 3.13.

Institutional Trading of Curis

Hedge funds have recently made changes to their positions in the company. Armistice Capital LLC lifted its position in shares of Curis by 8.7% during the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 78,265 shares during the last quarter. Maverick Capital Ltd. lifted its holdings in Curis by 7.8% during the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after purchasing an additional 49,554 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Curis by 37.3% during the fourth quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock valued at $238,000 after purchasing an additional 65,404 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in Curis by 2,883,237.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 230,659 shares during the period. Finally, Squarepoint Ops LLC boosted its position in Curis by 46.2% during the fourth quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 27,343 shares during the period. 29.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Zacks Research lowered shares of Curis from a “hold” rating to a “strong sell” rating in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $43.00 price objective (up from $17.00) on shares of Curis in a research note on Friday, July 24th. Wall Street Zen downgraded Curis to a “strong sell” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. One research analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and an average price target of $43.00.

View Our Latest Stock Analysis on CRIS

About Curis

(Get Free Report)

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.

Read More